These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8001405)

  • 1. [The rapid activation of human LAK cells and their inhibition on ovarian cancer at the advanced stage].
    Song YF; Zhao YN; Li J
    Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):332-5, 381. PubMed ID: 8001405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of lymphokine activated killer from umbilical blood on human ovarian cancer in nude mouse models].
    He YD; Peng ZL; Liu SL; Wang H; Pan XL
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep; 38(5):810-2. PubMed ID: 17953364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2.
    Horton SA; Oldham RK; Yannelli JR
    Cancer Res; 1990 Mar; 50(6):1686-92. PubMed ID: 2306722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental expansion and antitumor effects of LAK cells from cancer patient's peripheral blood].
    Zhang BX
    Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):253-6. PubMed ID: 1396072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells].
    Kikuchi Y; Oomori K; Miyauchi M; Kita T; Kuki E; Iwano I; Hirata J; Nagata I
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1891-5. PubMed ID: 2592812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-2 gene transfer in immunotherapy of cancer: local administration of IL-2-activated lymphocytes and X63-m-IL-2 cells constitutively producing IL-2 inhibits growth of plasmacytomas in syngeneic mice.
    Bubeník J; Lotzová E; Indrová M; Simová J; Jandlová T; Savary CA
    Nat Immun Cell Growth Regul; 1991; 10(5):247-55. PubMed ID: 1758466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].
    Duan DS
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):281-3, 314. PubMed ID: 8192930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
    Provinciali M; Di Stefano G; Stronati S; Fabris N
    Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Anticancer Res; 1990; 10(2A):441-6. PubMed ID: 2346317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of LAK cells and BRM on the growth of pancreatic cancer cells injected into nude mice].
    Asano H; Kobari M; Yusa T; Kawakami K; Matsuno S
    Nihon Geka Gakkai Zasshi; 1994 Sep; 95(9):678-88. PubMed ID: 7838109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-human lung giant cell cancer (PG) effect of human LAK cells in vitro and in nude mice].
    Deng HY
    Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):258-60. PubMed ID: 2272258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro experimental expansion and induction of LAK cell of lymphocytes from human carcinomatous ascites].
    Li DJ
    Zhonghua Zhong Liu Za Zhi; 1989 Nov; 11(6):433-6. PubMed ID: 2634542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The anti-pancreatic cancer efficacy of LAK cells mediated by YPC3 monoclonal antibody in vitro and in vivo].
    Chen QK; Yuan SZ
    Zhonghua Zhong Liu Za Zhi; 1994 Sep; 16(5):353-5. PubMed ID: 7895586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The anti-tumor efficacy of human recombinant interleukin-2 (rIL-2) in vivo].
    Wang C; Chai L; Zhu G
    Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):27-9. PubMed ID: 7656782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice.
    Ortaldo JR; Porter HR; Miller P; Stevenson HC; Ozols RF; Hamilton TC
    Cancer Res; 1986 Sep; 46(9):4414-9. PubMed ID: 3089592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell cycle assessment of adoptive transferred lymphokine activated killer cells.
    Watanabe R; Tanaka N; Naomoto Y; Moreira LF; Orita K
    Jpn J Clin Oncol; 1994 Apr; 24(2):59-65. PubMed ID: 8158860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.